当我国65岁以上人口占比逼近16%，2025年，骨科手术量正以年均8%的速度攀升至超352万台，但国内骨科 手术机器人却相较美国与欧洲，仍处于"叫好不叫座"的尴尬境地， 整体渗透率不足1%，远低于美国2026年 近20%的预期水平。 因为据不完全统计， 目前全国已有23个省份将骨科手术机器人相关费用纳入收费目录，收费价格在8000- 40000元，患者自费比例相对仍在降低。 如今，随着支付端政策破冰、技术壁垒突破与商业模式革新，骨科 机器人行业有望从"技术验证期"迈入"规模爆发期"，未来随着全国范围内支付端的持续改善，有望加速骨科 手术机器人应用渗透率的提升。 骨科手术机器人为何持续增长？ 01. 机器人大讲堂认为，骨科机器人的核心价值，始终围绕用技术精度破解临床痛点，而且近年来已经卓有成 效。传统骨科手术中，医生依赖经验完成的截骨、置钉操作，不仅面临"看不清、拿不稳、做不准"的困境， 还可能因人为误差导致神经损伤、假体松动等并发症 。而例如元化智能、天智航等国产骨科机器人凭借"脑 （控制系统）、眼（定位导航）、臂（机械臂）"的三位一体架构，已经实现了手术效率与安全性的双重飞 跃。 骨科手术面临多个技术与操作 ...

挥"农"墨于岭南 大地，执"工"笔 绘"两业融合"新 篇_南方+_南方 plus 南海之滨，改革 热土广东，一场 关于高质量发展 的宏大叙事正徐 数田垄与车间的 融合创新，正汇 聚成岭南大地向 上跃升的磅礴力 量。从近代"开 眼看世界"的前 沿，到今日探索 广东如何在"十 五五"开局之年 继续领跑？ "周虽旧邦，其 命维新。"《诗 经·大雅》中的 这句箴言，穿越 三千年时光，依 然铿锵有力。2 月24日召开的 2026年广东高质 量发展大会，将 主题聚焦于制造 业与服务业协同 发展。这既是广 东经济结构 向"新"而行的必 然选择，也是其 从规模领先迈向 质量领先的战略 升维。 这条主线，并非 悬于半空的宏大 叙事，而是深深 嵌入"百县千镇 万村高质量发展 工程"的实践沃 土。背后，是无 徐展开。作为全 国经济连续37年 的"第一引擎" ， 高质量发展的先 锋，广东正以融 合之道与育人之 智，破解发展不 平衡不充分的核 心课题，其探 索，关乎一省， 亦映照一国。 双轮驱动 产业链上握指成 拳 广东经济底盘 之"稳"，源于制 造业长期积累的 深厚根基；而其 发展动能 之"新"，则在于 服务业与制造业 的深度融合。 ...

Group 1 - The overall market size of surgical robots in China is expected to grow from 7.2 billion RMB in 2024 to 76.7 billion RMB by 2032, with a CAGR of approximately 34% [1] - The market for laparoscopic surgical robots is projected to have a CAGR of about 29% from 2024 to 2032, driven by the release of pricing directories and increased penetration rates [1] - The orthopedic surgical robot market is anticipated to grow at a CAGR of around 41% during the same period, supported by the implementation of pricing directories and increasing hospital admissions [1] Group 2 - CITIC Securities believes that surgical robots represent one of the best business models in the medical device sector, as installed equipment will drive continuous consumption of consumables, leading to stable revenue and cash flow [2] - The global market for leading surgical robot companies has surpassed 1 trillion RMB in market value, with significant growth potential in penetration rates and market size [2] - AI is expected to empower surgical robots to achieve autonomous operations, further assisting or replacing some surgical procedures performed by doctors, which will benefit industry penetration rates and enhance company valuations [2] Group 3 - Related Hong Kong stocks in the surgical robot sector include Precision Surgery-B (02675), MicroPort Scientific-B (02252), and Kangji Medical (09997) [3]

Market Overview - On February 10, the Shanghai Composite Index rose by 0.13%, while the Shenzhen Component increased by 0.02%, and the ChiNext Index fell by 0.37%[3] - The total trading volume on February 10 was 2.12 trillion yuan, a decrease of approximately 150 billion yuan compared to the previous trading day[1] Sector Performance - The media, home appliance, and coal sectors saw significant gains, while real estate, food and beverage, and agriculture sectors experienced declines[1] - Major inflows of capital were observed in the film and television, IT services, and publishing sectors, while outflows were noted in photovoltaic equipment, military electronics, and batteries[3] Market Sentiment - Market strength weakened compared to Monday, reflected in reduced gains and trading volume[1] - The rise in media and entertainment stocks is attributed to the Seedance 2.0 event and the pre-Spring Festival timing, indicating a short-term speculative nature[1] Investment Strategy - Given the market's recent adjustments, a shift away from short-term thinking is advised, focusing on opportunities post-holiday in sectors like technology, non-ferrous metals, and chemicals[1] - Over 60% of private equity firms prefer to hold significant positions during the holiday, with 70% optimistic about post-holiday market performance[12]

Core Viewpoint - The establishment of the international medical equipment and device trading platform in Tianjin aims to facilitate "global buying and selling" of medical devices and instruments, supporting the Chinese pharmaceutical industry's international expansion [1] Group 1: Platform Overview - The platform will provide services such as online display of pharmaceutical products, collection and publication of procurement and policy information, and analysis of market operation data [1] - It aims to lower international trade costs and enhance cross-border industrial cooperation through innovative cross-border procurement models and the establishment of procurement rules and standards [1] Group 2: Initial Transactions - The platform has already facilitated the first batch of transactions and procurement intention agreements involving fields such as orthopedic surgical robots, dental implants, and color Doppler ultrasound systems [1]

Core Viewpoint - The launch of the China International Medical Equipment and Devices Trading (Procurement) Platform in Tianjin aims to facilitate "global buying and selling" of medical equipment and devices, supporting the international expansion of China's pharmaceutical industry [1] Group 1: Platform Overview - The platform will provide services such as online display of pharmaceutical products, procurement information, policy information collection and publication, and market operation data analysis [1] - It is guided by the National Medical Insurance Administration to enhance the global competitiveness of Chinese medical products [1] Group 2: Strategic Goals - The platform aims to lower international trade costs through innovative cross-border procurement models, establishing cross-border procurement rules and standards, and promoting international pharmaceutical procurement cooperation [1] - It will also organize domestic and international exchange activities to deepen cross-border industrial cooperation [1] Group 3: Initial Transactions - The platform has already facilitated initial transactions and procurement intention agreements involving fields such as orthopedic surgical robots, dental implants, and color Doppler ultrasound systems [1]

21世纪经济报道记者唐唯珂 1月29日，三友医疗披露的业绩预告显示，2025年公司营业收入预计达5.35亿-5.62亿元，同比增长17.95%-23.90%；归母净利润更是实现5600 万-7280万元，较2024年的1146.86万元暴增388.29%-534.78%，扣非后归母净利润成功扭亏为盈。 2026年初，骨科赛道上市公司2025年度业绩预告密集披露，行业呈现"头部强者恒强、创新企业负重前行"的鲜明分化格局。 "无源+有源"疗法协同成为核心增长引擎，子公司水木天蓬的超声骨刀、超声吸引设备等产品营收与净利润快速增长，同时控股公司Implanet 的国际化业务表现亮眼，2025年营收1247.39万欧元，同比增长32.62%，其中美国市场增速高达49.30%，成为业绩重要增量。 春立医疗、三友医疗等龙头企业净利润实现数倍增长，奥精医疗成功扭亏为盈，核心受益于集采"以价换量"释放与国际化突破；而聚焦高端创 新赛道的天智航虽营收增速超50%，却仍未摆脱亏损困境。 春立医疗的业绩爆发力更为突出。2月3日披露的预告显示，2025年归母净利润预计为2.45亿-2.88亿元，同比增幅96.01%-130.41%；扣 ...

Core Viewpoint - The article provides a comprehensive overview of the approval status of surgical robots in China for the year 2025, highlighting the concentration of approvals in specific categories and the steady pace of regulatory processes throughout the year [2][5][9]. Summary by Sections 1. Approval by Category - The approval of surgical robots in 2025 shows a highly concentrated structure, with orthopedic surgical robots leading in the number of approvals, significantly surpassing other categories. Other categories such as puncture, endoscopic, and natural orifice approaches are in the second tier with single-digit approvals. Vascular intervention and neurosurgery products have relatively few approvals, indicating they are still in early development stages [5][9][10]. 2. Approval by Time - The distribution of approvals throughout 2025 indicates a stable and uniform rhythm, with no significant concentration in any single quarter or short-term window. Monthly fluctuations in approval numbers were minor, suggesting a normalization of the approval process rather than a surge driven by specific policy changes or concentrated applications [7][10][12]. 3. Annual Trend Assessment - The overall characteristics of surgical robot approvals in 2025 can be summarized as follows: - The number of approvals has maintained a steady pace without significant acceleration or inflection points, indicating a trend towards stable output rather than rapid expansion [10][11]. - The structural differentiation among categories is clear, with orthopedic products continuing to dominate the approvals [11][12]. - The approval rhythm has normalized, focusing more on specific products and application scenarios rather than short-term bursts of activity [12].

Core Insights - The article highlights that the Chinese surgical robot market is transitioning from an early development phase to a rapid growth phase, driven by the implementation of the medical insurance bureau's pricing policy and accelerated overseas market expansion [1][3]. Market Size and Growth - The Chinese surgical robot market is projected to grow from approximately 7.2 billion RMB in 2024 to 76.7 billion RMB by 2032, representing a compound annual growth rate (CAGR) of about 34% [2][5]. - In comparison, the global market is expected to increase from 21.2 billion USD to 75 billion USD during the same period, with a CAGR of around 17%, indicating that China's growth rate significantly outpaces the global average [2]. Market Segmentation - Laparoscopic surgical robots are expected to dominate the market, accounting for 58% of the total market size in 2024, with a projected CAGR of 29% from 2024 to 2032, reaching 32.1 billion RMB by 2032 [5]. - The orthopedic surgical robot market follows closely, with a market share of 26% in installed capacity and 22% in sales revenue. The CAGR for this segment is anticipated to be 41%, reaching 21.3 billion RMB by 2032 [5]. Policy Impact - The year 2026 is identified as a critical turning point due to the establishment of a national pricing framework, which will address the economic concerns of hospitals regarding the adoption of surgical robots [7][9]. - The medical insurance bureau's guidelines released on January 20, 2026, categorize surgical robots into four types and provide a clear reimbursement structure, which is expected to facilitate product adoption in hospitals [9]. International Expansion - The article notes that the Chinese surgical robot market currently accounts for only about 5% of the global market, indicating significant potential for overseas expansion [10]. - Leading domestic companies are rapidly entering international markets, with notable achievements such as MicroPort's 160 global commercial orders and the increasing share of overseas revenue for companies like Precision Medical [10]. Business Model - The surgical robot business model is likened to the "razor and blades" model, where the primary revenue source comes from consumables and services rather than just equipment sales [11][12]. - Companies are encouraged to focus on increasing installed base as a key indicator for future cash flow, with the potential for high-value orthopedic consumables sales being a critical factor for profitability [12].

Core Viewpoint - The domestic surgical robot industry is at a critical turning point from "concept validation" to "scale profitability" with the implementation of medical insurance policies and accelerated overseas market expansion [1] Market Size and Growth - The Chinese surgical robot market is projected to grow from 7.2 billion RMB in 2024 to 76.7 billion RMB by 2032, representing a compound annual growth rate (CAGR) of approximately 34% [2][3] - In comparison, the global market is expected to increase from 21.2 billion USD to 75 billion USD during the same period, with a CAGR of about 17%, indicating that China's growth rate significantly outpaces the global average [3] Segment Analysis - Laparoscopic surgical robots will dominate the market, accounting for 58% of the total market size in 2024, with a projected CAGR of about 29% from 2024 to 2032, reaching 32.1 billion RMB by 2032 [6] - The orthopedic surgical robot market follows closely, with a projected CAGR of 41% from 2024 to 2032, reaching 21.3 billion RMB by 2032 [6] Policy Impact - The year 2026 is identified as a pivotal moment for policy implementation, addressing the issue of "who pays" for surgical robots, which has been a barrier to adoption [8][9] - The release of the medical insurance guidelines on January 20, 2026, will clarify the reimbursement framework, significantly easing the entry barriers for surgical robots into hospitals [9] International Expansion - The Chinese surgical robot market currently accounts for about 5% of the global market, indicating substantial overseas market potential [10] - Leading domestic companies are rapidly expanding into international markets, with significant orders and certifications achieved, such as MicroPort's 160 global commercial orders and the CE certifications for various products [10][11] Business Model - The surgical robot industry follows a "razor and blades" business model, where the primary revenue comes from consumables and services rather than just equipment sales [12] - Companies are encouraged to focus on increasing installation base as a key leading indicator for future cash flow, similar to the strategy employed by Intuitive Surgical [12]